Basic Information
| LncRNA/CircRNA Name | XIST |
| Synonyms | XIST, DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66 |
| Region | GRCh38_X:73820651-73852753 |
| Ensemble | ENSG00000229807 |
| Refseq | NR_001564 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown etc. |
| Sample | cell lines (MGC803, BGC823, SGC-7901, AGS, KATOIII) |
| Expression Pattern | up-regulated |
| Function Description | A negative correlation was indicated between XIST and miR-185 in GC cells.In addition,TGF-B1 was predicted as a target gene of miR-185. miR-185 can modulate TGF-B1 expression negatively in vitro.Moreover, we found that sh-XIST inhibited GC development via decreasing TGF-B1 by upregulating miR-185 in vitro.Therefore,we speculated that XIST can act as a competing endogenous lncRNA (ceRNA) to regulate TGF-B1 by sponging miR-185 in GC.Taken these together,it was indicated that XIST/miR-185/TGF-B1 axis participated in the development of GC. XIST could act as a potential prognostic biomarker in GC development. |
| Pubmed ID | 29053187 |
| Year | 2018 |
| Title | XIST promotes gastric cancer (GC) progression through TGF-B1 via targeting miR-185. |
External Links
| Links for XIST | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |